Fraunhofer Institute for Cell Therapy and Immunology IZIAnnual report 2025/26
In 2025, Fraunhofer IZI’s patent portfolio consisted of 46 intellectual property families (excluding those managed by Fraunhofer IZI-BB), which are available for use in collaborative projectsas well as for direct marketing and licensing.
- Novel delivery systems for nucleic acids
- Methods, reagents / antigens and biomarkers for the diagnosis of various infections and other diseases for human and veterinary medicine
- New treatment methods for cancer and other diseases
- Mineral compounds for prevention / therapy of intestinal diseases
- RNA biomarkers for the prognosis of certain cancers
- Methods, biomarkers and device components for point-of-care diagnostics of infectious agents
- Drug / vaccine candidates for infectious and neurodegenerative diseases
- New viral vectors for gene modification of immune cells
- Optimized AAV vectors for the development of gene therapies, vaccines, and drug delivery systems
- Inactivation of pathogens in the context of vaccine production
- Novel ATMPs and methods for their optimization
- Epitopes from food relevant for the development of allergies and corresponding antibodies as a basis for allergy test developments
- Technologies for microfluidic systems
- Novel dialysis methods and novel components of dialysis systems
- Technical solution for the combination of amplification methods and LTF-based detection in one vessel for novel rapid infection tests
- Technical solution for alarm monitoring in automated laboratory systems